This article is more than 5 years old. Information may no longer be current.
Cardiology Today’s Intervention top 5 stories in November
Click Here to Manage Email Alerts
Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in November.
This month, Cardiology Today’s Intervention readers were most interested in data presented at TCT, including 1-year results of the BIONICS trial, final results of the RESPECT trial and quality-of-life outcomes for TAVR vs. surgery, as well as results presented at the American Heart Association Scientific Sessions, including PIONEER AF-PCI, the 1-year results of the GARY registry and much more.
PIONEER AF-PCI: Bleeding lower with rivaroxaban regimens in patients with AF needing PCI
NEW ORLEANS — Two anticoagulation strategies involving rivaroxaban conferred less bleeding risk than a strategy involving warfarin in patients with atrial fibrillation undergoing PCI with stenting, according to findings presented at the American Heart Association Scientific Sessions.
GARY: 1-year mortality higher with TAVR vs. surgery in real-world population
NEW ORLEANS — In a real-world population of patients with severe aortic stenosis, mortality at 1 year was higher after transcatheter aortic valve replacement compared with surgical aortic valve replacement.
Quality-of-life outcomes superior at 1 month for TAVR vs. surgery, but not at 2 years
WASHINGTON — Patients with severe aortic stenosis at intermediate surgical risk showed improved quality-of-life benefits at 1 month when treated with transcatheter aortic valve replacement compared with surgical AVR, but 2-year follow-up results showed similar quality-of-life outcomes, according to data presented at TCT 2016.
Ridaforolimus-eluting stent noninferior to zotarolimus-eluting stent for TLF at 1 year
WASHINGTON — One-year data from the BIONICS trial demonstrate that a ridaforolimus-eluting stent was noninferior to a zotarolimus-eluting stent for the primary outcome of target lesion failure in patients with complex CAD.
RESPECT final analysis: PFO closure reduces risk for recurrent stroke
WASHINGTON — Final results of the RESPECT trial showed that percutaneous patent foramen ovale closure reduced the risk for recurrent stroke compared with guideline-directed medical therapy alone over a mean follow-up of 6 years.